Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia
Phase of Trial: Phase I/II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs RGX 501 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- 04 Jan 2018 According to a REGENXBIO media release, company expects to complete enrollment in this trial in mid-2018 and top-line data is expected in late 2018.
- 08 Nov 2017 According to a REGENXBIO media release, review of data from the first cohort has been conducted by an independent DSMB, who has granted clearance to proceed to the next dosing cohort based on their assessment of the safety and tolerability data. The Company anticipates dosing of the second cohort in the trial to be initiated prior to year-end 2017.
- 08 Nov 2017 According to a REGENXBIO media release, the company expects to provide updates from the trial are anticipated by year-end 2017.